Nyxoah (NYXH) – Investment Analysts’ Weekly Ratings Changes

A number of firms have modified their ratings and price targets on shares of Nyxoah (NASDAQ: NYXH) recently:

• 8/17/2026 – Nyxoah had its price target lowered by Cantor Fitzgerald to $6.00. They now have an “overweight” rating on the stock.
• 8/9/2026 – Nyxoah was downgraded by Wall Street Zen from “hold” to “sell”.
• 8/6/2026 – Nyxoah was given a new $2.31 price target by Robert W. Baird.
• 8/6/2026 – Nyxoah had its “overweight” rating reaffirmed by Piper Sandler. They now have a $6.00 price target on the stock, down from $7.00.
• 8/6/2026 – Nyxoah was given a new $4.00 price target by Oppenheimer Holdings, Inc..
• 8/1/2026 – Nyxoah was upgraded by Wall Street Zen to “hold”.
• 7/9/2026 – Nyxoah was given a new $2.85 price target by Robert W. Baird.

Nyxoah SA, headquartered in Mont-Saint-Guibert, Belgium, is a medical technology company focused on neuromodulation therapies for sleep‐disordered breathing. Established in 2018, the company’s primary offering is the Genio® system, a minimally invasive bilateral hypoglossal nerve stimulator designed to treat moderate to severe obstructive sleep apnea (OSA). By electrically stimulating the genioglossus muscle, the device helps maintain airway patency during sleep, reducing apnea events and improving overall sleep quality.

The Genio system comprises a small, implantable stimulator positioned submentally and an external activation unit worn by the patient.